Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2012 Mar 19:38:9.
doi: 10.1186/1824-7288-38-9.

Multiple endocrine neoplasias type 2B and RET proto-oncogene

Affiliations
Review

Multiple endocrine neoplasias type 2B and RET proto-oncogene

Giuseppe Martucciello et al. Ital J Pediatr. .

Abstract

Multiple Endocrine Neoplasia type 2B (MEN 2B) is an autosomal dominant complex oncologic neurocristopathy including medullary thyroid carcinoma, pheochromocytoma, gastrointestinal disorders, marphanoid face, and mucosal multiple ganglioneuromas. Medullary thyroid carcinoma is the major cause of mortality in MEN 2B syndrome, and it often appears during the first years of life. RET proto-oncogene germline activating mutations are causative for MEN 2B. The 95% of MEN 2B patients are associated with a point mutation in exon 16 (M918/T). A second point mutation at codon 883 has been found in 2%-3% of MEN 2B cases. RET proto-oncogene is also involved in different neoplastic and not neoplastic neurocristopathies. Other RET mutations cause MEN 2A syndrome, familial medullary thyroid carcinoma, or Hirschsprung's disease. RET gene expression is also involved in Neuroblastoma. The main diagnosis standards are the acetylcholinesterase study of rectal mucosa and the molecular analysis of RET. In our protocol the rectal biopsy is, therefore, the first approach. RET mutation detection offers the possibility to diagnose MEN 2B predisposition at a pre-clinical stage in familial cases, and to perform an early total prophylactic thyroidectomy. The surgical treatment of MEN 2B is total thyroidectomy with cervical limphadenectomy of the central compartment of the neck. When possible, this intervention should be performed with prophylactic aim before 1 year of age in patients with molecular genetic diagnosis. Recent advances into the mechanisms of RET proto-oncogene signaling and pathways of RET signal transduction in the development of MEN 2 and MTC will allow new treatment possibilities.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Characteristic phenotype of MEN 2B including thickened lips with bumps.
Figure 2
Figure 2
Multiple pseudo-polyps and bumps on the tongue. The lesions are mucous ganglioneurofibromas and ganglioneuromas.
Figure 3
Figure 3
The first toe is longer than the others and there is a wide space between the first and second toe.
Figure 4
Figure 4
Enzymo-histochemical studies of MEN 2B intestinal innervation performed by acetylcholinesterase on suction rectal biopsies: giant ganglioneurofibroma. SM = submucous layer; AChE = acetylcholinesterase.
Figure 5
Figure 5
Enzymo-histochemical studies of MEN 2B intestinal innervation performed by acetylcholinesterase on suction rectal biopsies: multiple ganglioneuromas and ganglioneurofibromas are brown stained. SM = submucous layer.
Figure 6
Figure 6
Total thyroidectomy for a MEN 2B patient 3 years old. Macroscopic evidence of carcinoma in the right lobe. Homolateral lymphadectomy together with central compartment lymphadectomy has to be performed during thyroidectomy.

References

    1. Sipple JH. "The association of pheochromocytoma with carcinoma of the thyroid gland". American Journal of Medicine. 1961;31:163–166. doi: 10.1016/0002-9343(61)90234-0. - DOI
    1. Ihara M, Yamashita T, Okamoto T. et al."A nationwide clinical survey of patients with multiple endocrine neoplasia type 2 and familial medullary carcinoma in Japan". Japanese Journal Clinical Oncology. 1997;27:128–134. doi: 10.1093/jjco/27.3.128. - DOI - PubMed
    1. Martucciello G, Ceccherini I, Lerone M. et al." Pathogenesis of Hirschsprung's disease". Journal of Pediatric Surgery. 2000;35:1017–1025. doi: 10.1053/jpsu.2000.7763. - DOI - PubMed
    1. Romeo G, Ronchetto P, Lou Y. et al."Point mutations affecting the tyrosine kinase domain of the RET proto-oncogene in Hirscsprung's disease". Nature. 1994;367:377–378. doi: 10.1038/367377a0. - DOI - PubMed
    1. Martucciello G, Luinetti O, Romano P, Magrini U. "Molecular biology, basic research and diagnosis of Hirshsprung's disease". Pathologe. 2007;28(2):119–124. doi: 10.1007/s00292-007-0897-7. - DOI - PubMed

LinkOut - more resources